Bristol-Myers Squibb Company
Substituted naphthyridinone compounds useful as T cell activators

Abstract:

Disclosed are compounds of Formula (I): ##STR00001## or a salt thereof, wherein: R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK.alpha.) and diacylglycerol kinase zeta (DGK.zeta.), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.